Voyager Therapeutics, Inc.
VY1706
Alzheimer’s disease
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for VY1706 in Alzheimer’s disease are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The study is expected to enroll up to an aggregate of 18 patients across three cohorts, with the highest dose not exceeding 5 x 10 13 vector genomes per kilogram, the highest dose tested in non-human primates in the good laboratory practice”